Thursday, April 15, 1999 |
4:30 -
5:30 p.m. |
Summary
of Breakout Sessions |
| 8:00 - 8:10 a.m. |
Welcome and
Conference Objectives |
| 5:30 - 7:00 p.m. |
DINNER |
| 8:10 - 8:45 a.m. |
Plenary 1:
Historical Perspectives |
7:00 -
7:30 p.m. |
Keynote
Address: John F. Niblack, Ph.D.
Executive Vice President, Pfizer, Inc. |
| 8:45 -
9:00 a.m. |
Keynote
Address: Harold Varmus, M.D.
Director, NIH |
| 7:30 -
9:30 p.m. |
Plenary
4: Emerging Technologies: Insights Into Novel Biomarkers |
| 9:00 - 10:30 a.m. |
Plenary 2: The Need
and Prospects for Biomarkers in Therapeutic Development |
Friday, April 16, 1999 |
| 7:45 - 9:30 a.m. |
Plenary 5: Immune
and Inflammatory Markers |
| 10:30 - 10:45 a.m. |
BREAK |
| 10:45 - 11:00 a.m. |
Keynote Address:
Jane Henney, M.D.
Commissioner, FDA |
9:30
a.m. - 12:30 p.m. |
Concurrent
Breakout Sessions Toxicity; Osteoporosis; Cancer Therapeutics; Immune
Markers of Graft Dysfunction; Hepatitis C Virus; Autoimmune Diseases; Alcohol and Drug
Abuse; Stable Cardiovascular Disease; Establishing Research Infrastructure |
| 11:00 a.m. - 12:30
p.m. |
Plenary 3:
Opportunities for Developing Biomarkers for CNS Disorders |
| 12:30 - 1:30 p.m. |
LUNCH |
| 1:30 -
4:30 p.m. |
Concurrent
Breakout Sessions Chronic Lung Diseases; Pharmacodynamic Markers;
Neurodegenerative/ Neuropsychiatric; Acute Ischemic Coronary Syndromes; Cellular Markers
of Graft Function; Cancer Prevention; Joint Destruction and Repair; Severe Infections and
Septic Shock; Pain Assessment |
12:30 - 1:45 p.m. |
LUNCH |
| 1:45 - 2:45 p.m. |
Summary of Breakout Sessions |
| 2:45 - 3:45 p.m. |
Closing Session
Panel Discussion: Research Recommendations for Advancing the Biomarker Field |
